Μπορείτε να στέλνετε ειδήσεις και Δελτία Τύπου στο email μας.
Αν θέλετε να επικοινωνήσετε μαζί μας ή να στείλετε Δελτίο Τύπου πατήστε εδώ...pharmamarketingexpertsblog@gmail.com


Παρασκευή, 2 Ιουνίου 2017

Top 10 complaints about working in Biopharma






Most professional consulting groups have all commented about the serious shortfall of working for a biopharma company.  A biopharma professional developed a list of the most common complaints about working in marketing for pharma.  Here is the list…

1ne: Too many damn meetings!  By far this is the top complaint we have heard.  Pharma companies are matrix organizations which means meetings, a lot of meetings usually taking up employee calendars for days and weeks.

2wo Takes too long to implement programs.  This is a complaint I usually hear from digital marketers.  Digital marketing is about implementing with speed and testing new things. Unfortunately, pharma tends to move at a snails pace which frustrates employees.

Παρασκευή, 26 Μαΐου 2017

The 3 most desirable skills in the ‘new breed’ of pharma sales representative


Medicine is changing from a mass market to a target market model, where doctors are increasingly incentivised by patient outcomes, treatment protocols are defined by integrated delivery networks and face-to-face access is becoming more limited. The role of the sales rep is changing fast, and in the next five years, teams are likely to become smaller, agiler and more focused, due to improvements in systems and technologies.

Τετάρτη, 24 Μαΐου 2017

Top Medical Sales Companies to Work For – Best of 2017



Medical sales is an attractive industry – the autonomy, the money, the chance to work alongside doctors and make a difference. What’s not to love? But every medical sales professional knows that not all medical sales jobs are created equal. So where are the best medical sales jobs? Which employers are the most sought-after?
The Annual MedReps Best Places to Work in Medical Sales survey answers that question and more. After counting the votes, these companies came out on top: Medtronic, Johnson & Johnson, and Stryker. 

About the Survey

In Q4 of 2016, MedReps asked our community of medical sales talent to tell us where they’d most like to work. More than a third of the 1,200 respondents named their current employers. Others chose from a list of Fortune 500 companies and companies nominated by the Medreps community. Still others wrote in the name of their preferred employer. This gave us a long and varied list of potential winners to consider. In addition to the total number of votes received, we also factored in the number of employees voting for their current employer, as well as their comments, to determine the final list of winners.

Δευτέρα, 8 Μαΐου 2017

Αντιδράσεις των Φαρμακευτικών Εταιριών στα Νέα μέτρα Κυβέρνησης – Θεσμών για τα Φάρμακα



Τα νέα μέτρα για το φάρμακο έχουν προκαλέσει την έντονη αντίδραση της φαρμακοβιομηχανίας. Ο Σύνδεσμος Φαρμακευτικών Επιχειρήσεων Ελλάδος (ΣΦΕΕ) δηλώνει την έντονη δυσαρέσκειά του κάνοντας λόγο για οριζόντια μέτρα. Σύμφωνα με τον ΣΦΕΕ, «τα μέτρα αυτά δεν αποτελούν διαρθρωτικές αλλαγές, αλλά καθαρά βαριά φοροεισπρακτικά μέτρα, τα οποία δεν εξασφαλίζουν τη μείωση του clawback κατά 30%, που είναι και μνημονιακή υποχρέωση. Μάλιστα τα μέτρα αυτά θέτουν περιορισμούς στην είσοδο των νέων καινοτόμων φαρμάκων ή και την καθιστούν απαγορευτική, γεγονός που θα έχει άμεσες και δυσμενέστατες επιπτώσεις στους Έλληνες ασθενείς». Επιπλέον, αναφέρει ο Σύνδεσμος, πλήττουν την υγιή επιχειρηματικότητα, χωρίς όμως να εξασφαλίζουν ούτε στέρεα δημοσιονομικά οφέλη ούτε, το κυριότερο, καλύτερες υπηρεσίες υγείας στους ασθενείς. Εξαντλούν, τέλος, τη βιωσιμότητα των φαρμακευτικών εταιρειών, απειλώντας τις 86.000 θέσεις εργασίας που στηρίζει άμεσα και έμμεσα ο Κλάδος του Φαρμάκου και δημιουργούν συνθήκες αποεπένδυσης. 

Τι περιλαμβάνουν τα νέα μέτρα

Η συμφωνία μεταξύ κυβέρνησης και Θεσμών περιλαμβάνει νέα μέτρα με στόχο τη συγκράτηση της φαρμακευτικής δαπάνης και «όχημα» την αύξηση της χρήσης των γενοσήμων, τις μειώσεις τιμών στα αποζημιούμενα φάρμακα, αλλά και την απελευθέρωση των μη συνταγογραφούμενων φαρμάκων. 

Κυριακή, 7 Μαΐου 2017

Restricting pharmaceutical reps’ marketing tactics changes physician prescribing behavior

New research shows that limiting how pharmaceutical sales representatives can market their products to physicians changes their drug prescribing behaviors.
A team, led by the University of California, Los Angeles' Ian Larkin and Carnegie Mellon University's George Loewenstein, examined restrictions 19 academic medical centers (AMCs) in five U.S. states placed on pharmaceutical representatives' visits to doctors' offices. Published in the May 2 issue of the Journal of the American Medical Association, the results reveal that the restrictions caused physicians to switch from prescribing drugs that were more expensive and patent-protected to generic, significantly cheaper drugs.
Pharmaceutical sales representative visits to doctors, known as "detailing," is the most prominent form of pharmaceutical company marketing. Detailing often involves small gifts for physicians and their staff, such as meals. Pharmaceutical companies incur far greater expenditures on detailing visits than they do on direct-to-consumer marketing, or even on research and development of new drugs. Despite the prevalence of detailing and the numerous programs to regulate detailing, little was known about how practice-level detailing restrictions affect physician prescribing, until now.

Πέμπτη, 4 Μαΐου 2017

Έρευνα με μεγάλο ενδιαφέρον για τους εργαζόμενους των φαρμακευτικών εταιριών.



Η συμμετοχή σας θα ενισχύσει σημαντικά την αξιοπιστία των αποτελεσμάτων. 

Για να μάθετε περισσότερα, πατήστε στην παρακάτω εικόνα.

Κοινοποιήστε το και στους φίλους σας. 

 https://terpsika.wixsite.com/survey

Τετάρτη, 26 Απριλίου 2017

It is not a great time to be a pharmaceutical rep


By Martha Rosenberg*

More than a decade ago, the job of the pharmaceutical rep was enviable. Direct-to-consumer advertising pre-sold many drugs so doctors already knew about them. Medical offices welcomed the reps who were usually physically attractive and brought lunch. In fact, reps sometimes had their own reception rooms in medical offices.

By 2011 thanks to drug safety scandals and new methods of marketing, the bloom had fallen off the pharma reps’ roses. The number of prescribers willing to see most reps fell almost 20 percent, the number refusing to see all reps increased by half, and eight million sales calls “could not be completed” at all, reported ZS Associates.

Τρίτη, 18 Απριλίου 2017

The top 10 drug launches of 2017



After an unusually slow year for new drug approvals—the FDA greenlighted just 22 meds in 2016—it remains to be seen whether drugmakers can do much better in 2017. One thing’s for sure, though: No matter what total the industry tallies up this year, the crop will bring some would-be blockbusters and market disrupters.
At the top of the list, according to EP Vantage’s 2017 preview, which ranks the year’s rollouts by 2022 sales, is Ocrevus (ocrelizumab), the Roche multiple sclerosis drug that’s promising to shake things up in more ways than one. In clinical trials, the candidate bested Merck KGaA's standard therapy Rebif, and it’s also gone where no other MS drug has gone before, posting positive data in patients with the primary progressive form of the disease. Those data will put the heat on other meds—and invite payers to pile pressure onto the segment, too.

Δευτέρα, 3 Απριλίου 2017

Pharma's most-valuable brands 2017


U.S. pharma brands jumped in value almost across the board in Brand Finance's annual look at the nation’s most valuable. The lone exception? Valeant Pharmaceuticals
While Johnson & Johnson, Pfizer, Merck & Co., AbbVie, Eli Lilly and Bristol-Myers Squibb all gained brand value—$500 million, on average—Valeant dropped almost $1 billion. The embattled pharma went from $2.67 billion last year to just $1.48 billion in this year’s tally.
That's quite a turnabout: Just one year prior, Valeant had soared to join Pfizer at the top of the pharma chart, based at the time on its strategy of buying in drug development, with takeovers of Salix, Mercury Holdings and Sprout Pharmaceutical in 2015.
Brand value is different from reputation, which is why pharma could gain industrywide amid the drug-pricing controversy that raged almost all the way through 2016.
Brand Finance also tallies global brand value, and its worldwide pharma report, the top 10 global pharma brands, saw value increase unilaterally. Roche led global growth with a 56% increase in value at No. 1 and a $6.09 billion value.

Κυριακή, 2 Απριλίου 2017

What Are The Top-Selling Prescription Medications In History?



You may or may not be surprised to learn that Lipitor, a prescription medication for lowering bad cholesterol and manufactured by drug giant Pfizer, is the top-selling prescription drug of all time according to recent reports, which indicate the medication has brought in $148.7 billion in sales over the drug’s 21 years since it was approved in 1996.
What other prescription medications are the top sellers? Humira, Seretide, Remicade, Plavix, Enbrel, Rituxan, Herceptin, Avastin, and Nexium round out the top 10.
Humira, a drug from AbbVie Inc., is used for the treatment of a variety of conditions from arthritis and ulcerative colitis to plaque psoriasis and Crohn’s disease.
Seretide, also known as Advair, is a top-selling asthma inhaler drug from GlaxoSmithKline; a bronchodilator also used to treat COPD.
Remicade, manufactured by Janssen Biotech (formerly Centocor Ortho Biotech) is similar to Humira in that the drug is used to treat Crohn’s disease, plaque psoriasis, ulcerative colitis, and rheumatoid and psoriatic arthritis.
Plavix is a blood thinner brought to the market by Bristol-Myers Squibb and Sanofi SA, and is designed for patients with coronary artery disease and may help prevent heart attack, stroke, and other heart conditions.
Most people are familiar with most of these drugs, which have brought in billions in sales since approval. For instance, Humira was approved in 2003 and through 2016 had $95.6 billion in sales. Plavix was introduced into the pharmaceutical market in 1997, and has brought in sales of $82.3 billion.
While Lipitor is still a huge seller for Pfizer, the majority of sales are in overseas markets and China since the expiration of its patent in November of 2011.
Many believe that while our new President has vowed to bring down prescription drug prices, it won’t be an easy task, or one that’s tackled during his time in office, considering other obstacles such as trade and tax reform, changes to healthcare, and more.


http://farmakeftikomarketing.weebly.com/